Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Capital Expenditures (2019 - 2024)

Addex Therapeutics' Capital Expenditures history spans 6 years, with the latest figure at $1.5 billion for Q4 2024.

  • On a quarterly basis, Capital Expenditures fell 77.13% to $1.5 billion in Q4 2024 year-over-year; TTM through Dec 2024 was $1.5 billion, a 2017.52% increase, with the full-year FY2024 number at $1453.2, down 81.16% from a year prior.
  • Capital Expenditures came in at $1.5 billion for Q4 2024, down from $6.4 billion in the prior quarter.
  • The five-year high for Capital Expenditures was $6.4 billion in Q4 2023, with the low at -$5.5 billion in Q2 2023.
  • Historically, Capital Expenditures has averaged $101.7 million across 5 years, with a median of -$1818.8 in 2021.
  • Peak annual rise in Capital Expenditures hit 527315128.25% in 2023, while the deepest fall reached 127812814.85% in 2023.
  • Year by year, Capital Expenditures stood at $78252.8 in 2020, then tumbled by 46.49% to $41874.8 in 2021, then tumbled by 97.12% to $1205.1 in 2022, then surged by 527315128.25% to $6.4 billion in 2023, then plummeted by 77.13% to $1.5 billion in 2024.
  • Business Quant data shows Capital Expenditures for ADXN at $1.5 billion in Q4 2024, $6.4 billion in Q4 2023, and -$767.6 million in Q3 2023.